Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Sintilimab + mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT06572813Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, sintilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Started Nov 2024; status: recruiting.
02
Drugs
bortezomibsintilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06572813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572813.